GlassScriptPhysician profile
Scott A Mason
NPI 1609916444
$223.35
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.51 | 2021 | |
| Novo Nordisk INC | $42.77 | 2021 | |
| Lilly USA, LLC | $31.79 | 2021 | |
| Horizon Therapeutics Plc | $18.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.28 | 2021 | |
| Esperion Therapeutics, INC. | $15.01 | 2021 | |
| Dexcom, INC. | $12.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.84 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.14 | 2021 | |
| Abbvie INC. | $11.42 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.